



This is a repository copy of *Cancer cell dormancy in the bone microenvironment*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/233243/>

Version: Published Version

Article:

Harris, C.J. orcid.org/0000-0002-1808-5992, Stewart, G.R. orcid.org/0000-0001-7397-2132, Foston, A. orcid.org/0009-0000-4547-9252 et al. (1 more author) (2025) Cancer cell dormancy in the bone microenvironment. *Current Osteoporosis Reports*, 23 (1). 46. ISSN: 1544-1873

<https://doi.org/10.1007/s11914-025-00934-1>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>



Cancer Cell Dormancy in the Bone Microenvironment

Chloe J. Harris¹ · Georgia R. Stewart¹ · Abigail Foston¹ · Alanna C. Green¹

Received: 18 July 2025 / Accepted: 3 September 2025
© The Author(s) 2025

Abstract

Purpose of the Review Cancer cell dormancy in the bone microenvironment presents a major obstacle to curative therapy across multiple cancer types. The bone harbours specialised pro-dormancy niches that promote the induction and long-term maintenance of dormant cancer cells. Many cancers originate in or metastasise to bone, but share the phenomenon of dormancy, which enables therapy evasion and later reactivation to cause disease relapse. This review provides recent updates in preclinical and clinical findings regarding dormancy in bone.

Recent Findings Studies have identified specific cell types including bone lining cells and Nestin+NG2+MSCs as pro-dormancy niche cells. Newly identified signalling pathways, such as autophagy, have been found to support dormancy, with degrees of built-in redundancy. These advances have led to ongoing clinical trials in this space that mean new dormancy-targeting therapies, such as the autophagy inhibitor hydroxychloroquine, are on the horizon.

Summary This review explores extrinsic and intrinsic regulators of cancer cell dormancy in the bone microenvironment and highlights recent advances in development of therapies that can target cancer cell dormancy.

Keywords Bone metastasis · Cancer cell dormancy · Senescence · Myeloma · Breast cancer · Prostate cancer

Introduction

Cancer cell dormancy presents a major barrier to curative treatment of cancers that grow in the bone marrow microenvironment. This includes primary cancers like multiple myeloma, and also cancers that metastasise to bone, including breast and prostate cancer. Non-proliferative cells, whether dormant, senescent or quiescent, are largely resistant to therapies that target cycling cells. Dormant cancer cells are also relatively rare, making them challenging to target. Here we will discuss cancer cell dormancy, how it is regulated by the bone microenvironment and how recent progress in this area means that new treatments are on the horizon.

Defining Dormancy, Senescence and Quiescence

In cancer, dormancy can refer to two separate phenomena, tumour mass dormancy or cellular dormancy. Tumour mass dormancy occurs when the rate of cancer cell proliferation is balanced with cell death, causing no net change in tumour volume [1] and encompasses angiogenic and immune-mediated tumour dormancy (see review [2]). This definition evolved from the original theory of ‘population dormancy’ proposed in 1972 [3]. In comparison, cancer cell dormancy refers to individual cell(s) in reversible cell cycle arrest, that are capable of reactivation and tumour expansion [4], and will be the focus of this review.

Dormant cancer cells are non-cycling and thus share traits with healthy quiescent cells, senescent cells and to a lesser extent differentiated cells, and other somewhat synonymous terms including diapause-like, drug-resistant persister cells and cancer stem cells. The similarities and differences are well-described in previous reviews by Risson *et al.* [2] and Weston & Barr [5]. The key difference between dormancy and senescence is that cell cycle arrest in dormancy and quiescence is reversible, whereas the senescent state is considered permanent. Cellular dormancy can

Chloe J. Harris, Georgia R. Stewart and Abigail Foston contributed to the work (co-first authors).

✉ Alanna C. Green
a.c.green@sheffield.ac.uk

¹ Mellanby Centre for Musculoskeletal Research and Healthy Lifespan Institute, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield S10 2RX, UK

be triggered by environmental stresses and is widely considered to be a protective mechanism to encourage survival in the metastatic niche (Fig. 1). Senescence, an age-related stress response, can trigger cell cycle arrest to protect against further damage. Senescence in aging is initiated by telomere shortening, which triggers the DNA damage response to prevent any further replication from occurring and exacerbating damage, via its activation of ATM: HK2 and p53:p21 [6]. The senescent state can also be induced by a variety of stimuli (e.g. irradiation [7]), and the senescence-associated secretory phenotype (SASP) of a cell can be influenced by these factors. Senescence within cancer has been linked to immune evasion, as these cells can help to reprogram the immune landscape of the tumour microenvironment [8]. Similarly, there is overlap between cancer stem cells and dormant cells, but not all dormant cells display stem cell-like characteristics [4]. Moreover, while dormant cells survive chemotherapy, many treatments also induce a dormancy-phenotype but there are likely differences in dormancy regulation between these two scenarios. The shared traits and markers (e.g. Ki-67-, p21+, p27+) between

dormant, senescent and similar cells can make them difficult to distinguish and can sometimes lead to the terminology for these cells being interchanged.

Mechanisms of Cancer Cell Dormancy

Cancer cell dormancy is observed across cancer types and tissues, with the bone microenvironment in particular containing pro-dormancy niche(s), and the ability to trigger reactivation [4, 9]. The bone microenvironment is required for dormant cells to persist over long time periods and offers protection from drug treatments and immune surveillance.

Dormancy should also be thought of as a dynamic ‘on-off’ process, where cells can enter dormancy, reactivate and divide, then their progeny can re-enter dormancy. With dormant cells retaining the same capacity as proliferating cells to repopulate tumours in myeloma [10]. Cells can remain dormant for long periods of time (months-years), but specifics around dormancy dynamics are poorly understood.




Fig. 1 Cell cycle control in dormancy. Cellular dormancy is governed by a number of signalling pathways which decide whether the cell enters or exits G₀. These decisions are influenced by external factors such as cytokine signalling from surrounding cells, nutrient depletion, changes in blood supply, growth factors, damage inducers and therapeutics. These can affect the balance of Cyclin-dependent kinase (CDK) signalling, which is a key regulator of cell cycle progression. Increased p38 levels can lead to activation and accumulation of CDK interacting proteins/kinase inhibitory proteins (Cip/Kips) and CDK4 inhibitors (INK4s). These inhibit CDKs and contribute to quiescence

by maintaining retinoblastoma protein (Rb) mediated inhibition of E2F transcription factor coding genes. In contrast, heightened levels of extracellular signal-regulated kinases (ERK) boosts cyclin activity which acts to promote proliferation via hyperphosphorylation of RB. In order to progress from G₁ to S phase, the checkpoint needs to be passed. If p21 levels are too high, the cell is arrested. Similarly, the G₂/M checkpoint must be passed by accumulation of the CDK1/cyclin B complex for the cell to start division. Signals that can act to prevent this include myelin transcription factor 1 (Myt1) and Wee1. Created in BioRender. Green, A. (2025) <https://BioRender.com/nuy9a51>

Microenvironment Cell Regulation of Dormancy

Cancer cell dormancy is controlled by extrinsic signals from




Fig. 2 Extrinsic and intrinsic control of cancer cell dormancy in bone. **A** Dormant cancer cells reside in pro-dormancy niches, on the endosteal niche near bone lining cells and in breast cancer the perivascular niche. Proximal to endothelial cells (ECs) perivascular NG2+Nestin+ mesenchymal stromal cells (MSCs) promote dormancy via transforming growth factor (TGF)-β2 and bone morphogenetic protein (BMP)7. The role of immune cells, adipocytes and osteocytes are not yet well defined. **B** Reactivation can be triggered by induction of osteoclastic resorption by receptor-activated nuclear factor kappa-B ligand (RANKL), gonadectomy or interleukin (IL)-1B. **C** The endosteal pro-dormancy niche regulates dormancy via intercellular signal-

ling pathways. **D** Cell-intrinsic dormancy pathways. C-X-C chemokine receptor type 4 (CXCR4), CXC ligand 12 (CXCL12), vascular cell adhesion molecule 1 (VCAM1), growth arrest-specific 6 (GAS6), annexin A2 (ANXA2) receptor (ANXA2R), leukaemia inhibitory factor (LIF) receptor (LIFR), receptor tyrosine kinase-like orphan receptor 2 (ROR2), tripartite motif-containing protein 44 (TRIM44), nuclear receptor subfamily 2 Group F member 1 (NR2F1), hypoxia-inducible factor (HIF), signal transducer and activator of transcription (STAT), extracellular signal-regulated kinase (ERK), urokinase plasminogen activator receptor (uPAR), von Willebrand factor (vWF). Created in BioRender. Green, A. (2025) <https://BioRender.com/jndnuas>

homeostatic functions. Cancer cells take advantage of these niches, exploiting them to promote cancer cell persistence, survival and drug resistance. Many of the well-established mechanisms are discussed in a thorough review by Risson *et al.* [2] and we have focused on recent advances in the dormancy and senescence niche paradigm.

In bone marrow cancers, like myeloma and leukaemia, the primary site is the bone marrow, but these cancers still spread through multiple skeletal sites. In bone metastatic cancers, disseminated tumour cells (DTCs) will leave the primary tumour and spread via the circulation to bone. While many different cancer types grow in or spread to bone [11], the dormancy mechanisms have many similarities across cancer types despite the tissue of origin. In metastatic breast and prostate cancers, DTCs can be detected in the bone prior to overt metastasis [12–15]. Cancer cells can lie dormant for long periods of time, often causing the disease to return after years of remission for patients who achieved a ‘complete response’ (i.e. no detectable disease), or minimal residual disease (MRD [16–18], i.e. very low, usually stable, levels of disease). Dissemination to the bone is an inefficient process, only a small proportion of cells survive and repopulate tumours. However, we do not yet know whether dormancy is an entirely microenvironment-dependent process where chance engagement with the pro-dormancy niche is random, or whether the surviving dormant cells already exhibited intrinsic factors that encourage the dormancy-survival process. Moreover, the dynamics of dormancy in the bone marrow have not yet been characterised in detail *in vivo* in terms of duration of quiescent periods, the frequency of switching between quiescent and cycling state, and whether dormancy dynamics vary across sites in the skeleton. Given different skeletal sites have different niche and blood cell compositions [19, 20], and different responses to stress [20], it seems plausible that there could be site heterogeneity in single cell cancer dormancy dynamics in bone. The bone also reprogrammes DTCs for further spread to other soft tissue and skeletal sites. In bone metastatic breast and prostate cancer, enhanced activity of the histone methyltransferase enhancer of zeste 2 (EZH2) reprogrammes disseminated cells into a more stem-like phenotype, and elevates their capacity to seed other sites in mice, which can be prevented with an EZH2 inhibitor [21]. A related finding in patients is that endocrine therapies can induce epigenetic modifications, but not genetic alterations, that promote dormancy induction [22]. This indicates that dormancy is heavily influenced by extrinsic stimuli, and not a consequence of acquisition of mutations that promote a dormant state.

The bone marrow recruits cancer cells via chemoattractants usually involved in healthy haematopoiesis. This includes the C-X-C chemokine ligand 12 (CXCL12)-CXC receptor 4 (CXCR4) chemokine axis which recruits and

retains early B lymphocytes, plasma cells and haematopoietic stem cells (HSCs) in the bone marrow [23, 24]. DTCs typically engage in the endosteal and/or perivascular niches [10, 24–27] when they arrive in the bone marrow, where they can be maintained in a dormant state for extended periods of time. Generally, the mesenchymal/osteoblast lineage have most consistently been implicated in promoting/maintaining dormancy in the bone microenvironment across different cancer types [10, 23, 26–30], although whether there is one pro-dormancy niche, or multiple niches and the specific cell type(s) involved is an ongoing area of research (Fig. 2A). Dormant cells have been shown to reside near type I collagen (Col2.3 GFP+) [10], osteopontin [23, 26] and ALCAM-expressing cells [27, 28] on the endosteal surface, and osteoblasts protected cancer cells from oxidative damage [26] and hypoxia [28]. Bone lining cells are heterogeneous cell populations [19], and the pro-dormancy niche is likely a particular subset of these cells, as has been shown for the pre-B lymphocyte niche which is supported by AB bone lining cells (Lin-CD31-CD51+Sca-1-PDGFR α -PDGFR β +) [19]. In breast cancer, dormant cells are also in close proximity to endomucin+perivascular niches [23] and specifically regulated by NG2+Nestin+ mesenchymal stromal cells (MSCs) [31]. The perivascular niche is protective to breast DTCs in the bone marrow [32, 33] providing integrin-mediated resistance to chemotherapy, irrespective of whether they are dormant (p27+) or cycling (p27-), and targeting endothelial-derived von Willebrand factor and vascular cell adhesion molecule 1 (VCAM1) sensitised mice to chemotherapy to prevent bone metastases [33]. Recently, bone metastases with different primary origins were shown to display one of three distinct immune ecosystems, that were enriched for either macrophages & osteoclasts, monocytes, or regulatory & exhausted T cells [34]. The dormancy niche was not studied, but dormancy is likely influenced by these unique enrichments of different immune cell types.

The bone niche produces several pro-dormancy factors (Fig. 2A, C) that enable niche engagement (e.g. CXCL12) and maintenance of dormancy [e.g. growth arrest-specific 6 (GAS6) [29, 35], bone morphogenetic protein 7 (BMP7) [31, 36], transforming growth factor (TGF)- β 2 [31, 37], leukaemia inhibitory factor (LIF) [38]. A pathway that is implicated in dormancy maintenance across multiple cancer types in bone is GAS6 expressed by osteoblast lineage cells and also breast cancer cells [39], binding to TYRO3, AXL or MER (TAM) tyrosine kinase receptors, although the type of receptor expressed varies across cancer types. The AXL-Gas6 axis is important in myeloma and prostate cancer cell dormancy [29, 40, 41], and similarly the MER-GAS6 axis promotes dormancy in acute lymphoblastic leukaemia [42]. AXL inhibitor treatment in mice, reduces the proportion of dormant myeloma cells and increases tumour

burden, suggesting disruption of the AXL-GAS6 axis inhibits dormancy and thereby triggers reactivation [29]. In breast cancer, TGF- β 2 and BMP7 derived from NG2+/Nestin+ MSCs maintains dormancy. Indeed, deletion of periaarteriolar NG2+ cells using inducible or conditional deletion of TGF- β 2 in mice prior to intracardiac injection of E0771-GFP breast cancer cells, reduced the number of p27+ dormant cells and increased prevalence of bone metastasis [31]. While these studies show disruption of AXL in myeloma [29], or NG2+ MSC TGF- β 2 expression can reactivate dormant cells, not all cells were awakened. It is now evident that a multitude of factors are implicated in the pro-dormancy niche, meaning dormancy maintenance is a multi-factor process and is not completely dependent on any one pro-dormancy signal. In breast cancer, Ren *et al.* identified genes upregulated by dormant cells isolated from the bone of mice with PyMT-B01 cells [39], and their dormancy gene signature correlated with better outcomes in patients. However, knockdown or overexpression of each of these genes (*Cfh*, *Gas6*, *Mme*, *Ogn*) individually in breast cancer cells had no measurable impact on tumour burden when implanted into mice, although dormant cell numbers were not reported in this study. AXL knockout in prostate cancer cells does not alter dormancy induction [41]. While this possibly indicates that each of these genes are a consequence but not cause of dormancy, they also support the notion that dormancy is dependent on the niche, and cell dormancy is a multi-factor process with built-in redundancy.

Dormant cells can be reactivated by signals that trigger cell cycle re-entry (Fig. 2B). In bone, a well-established mechanism of dormancy exit in myeloma, breast and prostate cancer is through stimulation of osteoclastic resorption. This can be induced with the osteoclastogenic factor receptor-activated nuclear factor kappa-B ligand (RANKL) [10], castration [43] or ovariectomy [44], which can be inhibited with anti-resorptives zoledronic acid or OPG-Fc [45]. A recent trial demonstrated adjuvant zoledronic acid reduced DTCs in breast cancer patients with DTC-positive bone marrow [46]. Currently, the molecular mechanism of reactivation following resorption is unclear, but could be due to release of growth factors from the bone matrix that promote cell cycle re-entry, or disruption of the pro-dormancy niche. Microenvironment-derived interleukin (IL)-1B also promotes development of breast cancer bone metastases in mice via Wnt signalling [47–50]. Interestingly, tumour and microenvironment-derived IL-1B has the opposite effect in the primary tumour, where infiltration of anti-tumour immune cells impairs tumour growth. Inhibition of IL-1B with anakinra could prevent development of bone metastases when combined with zoledronic acid and doxorubicin [47]. In breast cancer, micrometastases form in the osteogenic niche near active osteoblasts [25], and the cancer cells

rely on transfer of calcium via connexin 43 gap junctions [51]. Therefore, a change in tumour-microenvironment signalling within the pro-dormancy niche can initiate the switch from quiescence to cell cycle re-entry.

Recent developments have identified that a senescent microenvironment promotes progression and proliferation in myeloma. Myeloma cells induced a senescence-like phenotype in bone marrow adipocytes, which in turn induced resistance to dexamethasone [52]. Myeloma is preceded by a premalignant condition monoclonal gammopathy of undetermined significance (MGUS), with a yearly 1% risk of progression from MGUS to myeloma. In patients with senescent MSCs the risk of progressing from MGUS to myeloma was higher. Senescent (β -galactosidase+) bone marrow MSCs promoted proliferation of myeloma cells, through upregulation of senescence factors including Gremlin-1 [53]. While an aged, senescent phenotype of microenvironmental cells promotes progression of myeloma, this may not be the case when the senescent phenotype is exhibited by plasma cells. Borges *et al.* recently showed that plasma cells from MGUS and myeloma patients exhibit a senescence-like phenotype based on several senescence gene lists compared to healthy plasma cells [54]. The senescence phenotype was higher in patients with stable MGUS compared to progressive disease [54], aligning with other studies showing the SASP phenotype aids in clearance and cellular turnover via immune activation [55]. An interesting finding was that the senescent plasma cells had a paracrine effect inducing senescence in surrounding microenvironmental cells [54]. It should be noted that, the senescence traits have considerable overlap with traits of dormant cancer cells (e.g. p21+, Ki-67-), and dormancy gene sets similarly show survival advantages in patients [29, 39].

Extrinsic Dormancy Factors

Beyond cellular interactions, extrinsic factors of the tumour microenvironment can induce or regulate dormancy including extracellular matrix (ECM) composition, hypoxia, nutrient availability and therapeutics (Fig. 2D). These are common methods for inducing dormancy *in vitro* [56], but not all these mechanisms have been studied and validated in the bone microenvironment *in vivo*. For instance, the bone microenvironment contains a complex ECM. Yet while the ECM controls dormancy at other sites [57–60], and integrins are important for bone metastasis [61], it is not clear whether the bone ECM directly regulates dormancy.

Oxygen levels regulate cellular metabolism and control of quiescence and proliferation. Compared to normal tissues (2%–9%), the concentration of oxygen in the bone marrow is low (hypoxic, <1%–6%) [62]. Hypoxia is critical for

the maintenance of quiescence in healthy stem cells, and hypoxia also supports cancer stem cells and chemotherapy resistance [63]. In myeloma, hypoxia induces stem cell-like features [64, 65] and stabilisation of hypoxia inducible factor (HIF)1 α by the deubiquitinase tripartite motif-containing protein 44 (TRIM44) maintains quiescence *in vivo* [28]. In breast cancer, hypoxia induces dormancy in the primary site and in DTCs, and cells remain dormant even once hypoxia is removed [66], however prolonged hypoxia downregulates LIF receptor (LIFR) triggering escape from dormancy and formation of bone micrometastases [38] (Fig. 1D).

Cancer therapeutics themselves can also induce dormancy in multiple cancers. In myeloma, standard of care treatments bortezomib or melphalan have been observed to induce a dormancy-phenotype in surviving bone-resident cells [67, 68]. These findings highlight the complex challenge of eliminating all cancer cells to ensure relapse prevention.

Intrinsic Dormancy Control

Intrinsically, cellular replication or quiescence/arrest decisions are tightly governed by the presence of CDKs and their associated cyclins (Fig. 1) [69]. Specific thresholds of cyclins and CDKs are required to pass each cell cycle restriction point to allow cell cycle entry and proliferation [70]. Specifically, increased cyclin-D increases CDK4/6 which phosphorylate the transcriptional repressor Rb and enable expression of downstream proliferation factors [71]. Conversely, reduced CDK activity confers normal quiescence and cancer dormancy [5]. A large variety of intra- and extra-cellular signalling pathways [9, 72, 73], converge on CDK regulation to allow dynamic cell cycle control in response to cellular conditions. The cyclin D/CDK4/6–Rb protein pathway is critical to the proliferation of both normal and malignant breast epithelial cells [74]. Inhibiting CDK4/6 with FDA-approved agents (e.g. abemaciclib, palbociclib [75], and ribociclib) combined with hormonal therapy, has proven effective in treating HR⁺ metastatic breast cancer [9] by preventing Rb phosphorylation and inducing G₁ cell cycle arrest [74], supporting the role of CDK4/6 in dormancy regulation. Regardless of stimuli, cancer dormancy pathways largely intersect on p38 and ERK regulation which respectively decrease CDKs and promote cyclin expression (Fig. 1) [76], with this balance controlling dormancy maintenance and release. The maintenance of this anti-proliferative signalling is essential to enable the long-term viability of dormant cancer cells.

Genetic, Epigenetic and Transcriptomic Alterations

Genetic heterogeneity is conserved within proliferative and dormant drug-tolerant states [77], and instead dormancy decisions are determined by epigenetic and transcriptional alterations. Evidence from breast cancer shows stochastic entry and asynchronous exit from dormancy under uniform conditions [22], reinforcing the theory that dormancy dynamics are driven by epigenetic and transcriptional reprogramming.

Epigenetic regulation is largely controlled by histone methylation and acetylation which dictate accessibility of the DNA to control transcription [78]. Use of histone deacetylase inhibitors (HDACi) in breast cancer, can induce LIFR and consequently pro-dormancy mechanisms [38, 79, 80]. Similarly, in prostate cancer HDACi repress metastatic outgrowth in bone through restoration of interferon signalling [81]. HDACi are also approved for use in myeloma, but the effect on dormant cells has not been investigated. Moreover, the histone methyltransferase Smyd5 maintains breast cancer dormancy, and similarly the histone methylation inhibitor 5-azacytidine facilitates maintenance in breast cancer and head and neck squamous cell carcinoma (HNSCC) [82, 83]. A combination of 5-azacytidine and all-*trans* retinoic acid (ATRA) increased expression of nuclear receptor subfamily 2 Group F member 1 (NR2F1) maintaining dormancy via SOX9 and retinoic acid receptor (RAR) β in prostate cancer and HNSCC [84, 85].

Dormant cancer cells in the bone microenvironment exhibit a unique transcriptome compared to their proliferating counterparts. In myeloma, single cell RNA sequencing revealed dormant cells (DiD^{hi}, 5TGM1 mouse model) express a transcriptome signature that is more akin to myeloid lineage cells including monocytes and macrophages [29]. In prostate cancer bone metastases, dormant cells (PGH⁺, RM1 mouse model) were enriched for genes involved in type I interferon signalling, and loss of this signature led to overt bone metastases [81]. Inflammatory and immune signatures are also enriched in dormant breast cancer cells (DiD⁺ cells, PyMT-B01 mouse model) [39]. Thus, while not identical, there are several genes and pathways that are consistently altered in dormant cells across cancer types, including the AXL-GAS6 axis. The precise mechanism that switches on these gene signatures has not yet been fully elucidated, but is thought to be microenvironment induced, and various microRNAs have also been implicated in transcriptional regulation and dormancy induction [86, 87].

Signalling Mechanisms and Metabolism

Pro-dormancy cues ultimately lead to induction and long-term maintenance of cell cycle arrest. Several pathways (e.g. TGF- β 2:TGBRIII, BMP7:BMPRII [40], LIF: LIFR [38]) converge at central dormancy-proliferation mediators, such as p38, ERK and STAT3/AKT to enable long-term dormancy survival (Fig. 2D). Downregulation of urokinase-type plasminogen activator receptor (uPAR) has been shown to reduce ERK signalling and drive dormancy maintenance through inhibition of the Src kinase/focal adhesion kinase pathway [88, 89], and *in vivo* targeting of Src and MEK1/2 prevented reactivation and metastasis [90, 91]. However, to date there has been little progress in therapeutic approaches targeting these signalling axes for cancer dormancy within bone.

Dormant cancer cells are dependent on autophagy, a process of cellular recycling of dysfunctional or unnecessary organelles and proteins [92]. Given dormancy can be a response and route to survive therapy, autophagy may offer a mechanism for cells to recover from oxidative/metabolic stress. Targeting autophagy, and in particular mitophagy, with hydroxychloroquine or knockdown of autophagy-related gene 7 (ATG7) caused accumulation of dysfunctional mitochondria and oxidative stress sufficient to induce apoptosis [92], highlighting a novel therapeutic avenue. Similarly, autophagy induction through increasing tumour suppressor aplasia Ras homolog member I (AHR1) in ovarian cancer promoted dormancy [93]. While these studies have not focused specifically on bone, autophagy is likely a general intrinsic stress-response mechanism, and not microenvironment-specific.

Pancreatic endoplasmic reticulum kinase (PERK) has also been identified as a regulator of survival in tumorigenic and “spontaneous” dormant human epidermoid carcinoma HEp3 cells both *in vitro* and *in vivo* [94, 95]. While PERK is significantly involved in the unfolded protein response (UPR) [96], survival of dormant cells is likely facilitated through its functions in autophagy and oxidative stress regulation [97]. Quiescent cells undergo metabolic shift away from glucose dependency to favour oxidative phosphorylation elevating ROS production, often induced by hypoxia [98, 99]. The master antioxidant transcription factor NRF2 is a direct target of PERK. PERK deletion caused inactivation of NRF2, resulting in attenuated growth and increased oxidative stress [100]. As such the dual protective role of PERK has been proven significant in dormant cancer cell survival [94, 95]. Calvo *et al.* (2023) recently showed selective *in vivo* depletion of HER2+ breast cancer DTCs in bone marrow and lung with PERK inhibitor HP40 treatment [101]. This was mirrored using spontaneously dormant D-HEp3 HNSCC cells [101], highlighting PERK as

a possible novel therapeutic target for dormant cell specific toxicity.

Clinical Trials Targeting Cellular Dormancy in Bone Metastatic Cancers

Advancements in our understanding of dormancy biology has led to development or redeployment of several therapeutics in clinical trials (Table 1). Current strategies to eliminate dormant cancer cells fall into three main categories: (1) directly targeting dormant cells, (2) preventing reactivation, or (3) inducing reactivation to sensitize them to therapies targeting proliferating cells (Fig. 3). The latter approach is considered risky, as even a small subset of treatment-refractory/resistant proliferating cells could potentially drive incurable recurrent disease. As yet, there are no NICE or FDA-approved strategies that directly target dormant cancer cells, although some therapies can impair reactivation.

A challenge in the development of therapies that target dormant cells is the need to reach every individual cancer cell, along with heterogeneity. Genomic analysis of samples across different skeletal sites in individual myeloma patients [102], or in melphalan-surviving clones [103, 104], indicate that relapse can be driven by a single clone and thus one dormant cell is sufficient to initiate relapse. As such, it is expected that complete elimination of dormant cells in all patients may require combination therapy in most patients.

Therapies to Prevent Reactivation

Therapies that prevent reactivation of dormant cells can prolong survival by inhibiting relapse and metastatic outgrowth in bone. A number of strategies appear to be effective pre-clinically and have promising results in trials assessing bone metastasis.

CDK4/6 Inhibitors

In advanced/metastatic breast cancer, CDK4/6 inhibitors (CDK4/6i) are approved in the UK for use in HR+HER2-breast cancer, either in previously untreated patients or following endocrine therapy, in combination with fulvestrant or aromatase inhibitors [108, 109, 111, 112, 115]. The PALOMA-2 trial showed that palbociclib plus letrozole extended median progression free survival (mPFS) by 36.2 months and reduced disease progression risk by 59% in patients with low-burden bone-only disease compared to letrozole alone [116, 117]. In comparison, adjuvant trials in early breast cancer have shown only modest

Table 1 Therapies targeting cancer cell biology in clinical trials. Original table

Drug	Clinical trial	<i>n</i>	Patient characteristics	Study design	Primary endpoints	Ref.
Palbociclib	Phase II Completed	60	RB + mHSPC	Palbociclib plus ADT vs. ADT	PSA RR after 28 days	[124]
Palbociclib	Phase II Active-not recruiting	-	mCRPC	Palbociclib	Clinical benefit rate, CR, PR, SD	(NCT02905318)
Palbociclib	PALOMA-2 Phase III Completed	666	postmenopausal women, ER+, HER2- MBC, no prior treatment for MBC	palbociclib plus letrozole vs. placebo plus letrozole	PFS assessed by the investigators	[116, 117]
Palbociclib	PALLAS Phase III Completed	5,761	ER+, HER2- EBC	Palbociclib plus adjuvant ET vs. adjuvant ET	iDFS	[120]
Palbociclib	PENELOPE-B Phase III Completed	1,250	ER+, HER2- High risk primary BC without a response to Taxine containing neoadjuvant chemotherapy	Palbociclib plus ET vs. placebo plus ET	iDFS	[121]
Abemaciclib	monarchE Phase III Ongoing	5,637	ER+, HER2-, node + high risk EBC	Abemaciclib plus ET (physicians' choice) vs. ET (physicians' choice)	iDFS	[118, 140]
Abemaciclib	CYCLONE 2 Phase III Active not recruiting	393	mCRPC, measurable disease and radiographic progression	Abemaciclib plus abiraterone and predniso(lo)ne vs. Placebo plus abiraterone and predniso(lo)ne	rPFS assessed by the investigators	[123]
Ribociclib	Phase Ib/II Completed	-	mCRPC chemotherapy naive RB + patients	Ribociclib plus enzalutamide	Maximum tolerated dose PSA Reduction	NCT02555189
Ribociclib	Phase Ib/II Complete	43 30 phase II	mCRPC in chemotherapy naive with progression on ARSI	Ribociclib plus docetaxel	6-month rPFS	[125]
Ribociclib	NATALEE Phase III Completed	5,101	ER+, HER2- EBC	Ribociclib plus NSAI vs. NSAI	iDFS	[119]
Elacestrant	EMERALD Phase II Completed	477	MBC ER+HER2- with 1–2 prior lines of therapy, including CDK 4/6i	Elacestrant vs. standard of care (SOC) endocrine monotherapy (fulvestrant/AI),	PFS assessed by blinded independent central review (BICR)	[141]
Giredestrant	acelERA Phase II Completed	303	MBC ER+HER2- with 1–2 prior lines of therapy, including at least 1 ET	Giredestrant vs. physician's choice ET	PFS assessed by the investigator in the overall population	[142]
Giredestrant	coopERA Phase II Completed	221	Untreated EBC and baseline Ki67 ≥ 5%	Window-of-opportunity phase with 14 days of giredestrant vs. anastrozole followed by 16 weeks of continued ET plus palbociclib	Ki67 change from baseline to week 2	[131]
Giredestrant	lidERA Phase III Active-recruiting	~4100	ER + HER2- Medium- and high-risk EBC	Giredestrant vs. physician's choice of ET	IDFS	NCT04961996, [132]
Imlunestrant	EMBER-4 Phase III Active-recruiting	~6000	ER + HER2- EBC with adjuvant ET for 2–5 years and increased risk of recurrence	Giredestrant vs. standard ET	IDFS	NCT05514054, [133]

Table 1 (continued)

Drug	Clinical trial	<i>n</i>	Patient characteristics	Study design	Primary endpoints	Ref.
Hydroxychloroquine	Phase I Completed	14	ER+HER2- MBC	Hydroxychloroquine plus palbociclib plus letrozole	Safety and Tolerability Recommended phase II dose	[135]
Hydroxychloroquine	Phase I Active- not yet recruiting	TBC	Resectable, localised PC	Hydroxychloroquine vs. placebo	Change in expression of autophagy markers	<i>NCT06408298</i>
Hydroxychloroquine	CLEVER Phase II Completed-follow-up results to come		High Risk TNBC diagnosed within 5 years with positive nodes post completed neoadjuvant therapy except ET with detectable bone DTCs	Hydroxychloroquine or everolimus (mTOR inhibitor) or Hydroxychloroquine plus everolimus	Feasibility as defined at >75% completion of C6C without G3/G4 AE	[143]
Hydroxychloroquine	ABBY Phase II Active- Recruiting	TBC	Histologically confirmed BC that has completed all primary treatments and has no evidence of recurrent local or distant BC.	Hydroxychloroquine plus abemaciclib vs. abemaciclib	Incidence of treatment-emergent adverse events Change in number if DTCs	<i>NCT04523857</i>
Hydroxychloroquine	PALAVY Phase II Active- Recruiting	TBC	ER+EBC with detectable DTCs in the bone marrow	Hydroxychloroquine or Avelumab (PD-L1 inhibitor) with or without Palbociclib	Proportion of subjects in each treatment arm with clearance of DTC at the end of the 6 cycles	<i>NCT04841148</i>
Hydroxychloroquine	Phase II Completed	52	PC with rising PSA after primary therapy- no radiographic evidence of metastasis and no ADT within 3 months	Hydroxychloroquine	PSA Response	[136]
Hydroxychloroquine	Phase II Completed	19	Oligometastatic PC (<5 synchronous metastatic lesions) following primary tumour treatment	Hydroxychloroquine for 2 weeks prior to metastatic site directed radiotherapy	≥50% induction of PAR-4 expression above baseline	[138]
HC-5404 (PERKi)	Phase Ia Completed	23	Advanced solid tumours	Dose escalation of HC-5404	<i>MTD, safety and tolerability</i>	[139]
AZA and atRA	Phase II Completed	14	PC post-local therapy with rising PSA (PSADT<10 mo)	AZA & atRA vs. observation	safety and tolerability	[134]
Zoledronic acid	Phase II completed	45	BC Stage I-III with >4 MM/mL DTC at baseline	Zoledronic acid	DTC and CTC measurement	[46]

ADT Androgen Deprivation Therapy; *ARSI* Androgen Receptor Signalling Inhibitors; *BC* Breast Cancer; *CTC* Circulating Tumour Cell; *DLT* Dose Limiting Toxicity; *DRFS*; *DTC* Disseminated Tumour Cell; *EBC* Early Breast Cancer; *ER* Oestrogen Receptor; *ET* Endocrine Therapy; *iDFS* Invasive Disease-Free Survival; *MBC* Metastatic Breast Cancer; *mCRPC* Metastatic Castrate-Resistant Prostate Cancer; *mHSPC* Metastatic Hormone Sensitive Prostate Cancer; *MTD* Maximum Tolerated Dose; *NSAI* Non-Steroidal Aromatase Inhibitors; *ORR* Overall Response Rate; *PC* Prostate Cancer; *PFS* Progression-Free Survival; *PSA* Prostate Specific Antigen; *RB* Retinoblastoma; *rPFS* Radiological Progression-Free Survival; *RR* Response Rate; *TBC* To Be Confirmed; *TNBC* Triple Negative Breast Cancer

(monarchE [118]), NATALIE trials [119]) or no (PALLAS [120], PENELOPE-B [121]) improvement in survival outcomes. However, these trials resulted in the recommended use of adjuvant abemaciclib with endocrine therapy in HR+HER2- early breast cancer at high risk of recurrence [122]. Guidelines regarding use of adjuvant ribociclib with

an aromatase inhibitor for HR+HER2- early breast cancer are soon to be announced [115]. The effectiveness of CDK4/6i at preventing bone metastatic outgrowth is likely via preventing dormancy reactivation, although has not been assessed clinically.




Fig. 3 Strategies to target dormant cancer cells based on dormant cell biology. **1** Directly targeting dormant cancer cells offers a strategy to completely eliminate dormant residual disease. Autophagy inhibitors and/or PERK inhibitors are promising therapies which disrupt survival mechanisms that dormant cells rely on during metabolic stress (autophagy and the unfolded protein response (UPR), respectively) [92, 101, 105–107]. **2** Preventing reactivation of dormant cancer cells offers a strategy to maintain dormancy and prevent relapse. CDK4/6 inhibitors, selective oestrogen receptor degraders (SERDs), bisphosphonates and 5-azacytidine and all-*trans* retinoic acid (ATRA), are promising/approved therapies that interfere with key pathways involved in dormancy, such as inhibiting cell cycle re-entry [108–114], epigen-

etic reprogramming via NR2F1 via SOX9 and RARβ [84, 85], and inhibiting the supportive osteoclastic resorption that induces tumour proliferation in the bone microenvironment [46]. **3** Inducing reactivation of dormant cancer cells offers a strategy to induce the dormant cell population into a proliferative cell population that is more susceptible to standard chemotherapeutic treatment. Strategies such as using RANKL and IL-1B to stimulate osteoclastic resorption [10, 48–50], and TGF-β2 inhibitors which block pro-dormancy signals from mesenchymal stromal cells (MSCs) [40], both are promising strategies to reactivate the dormant cells back into the cell cycle. Therapies in green are approved, therapies in blue are in preclinical or clinical trials. Created in BioRender. Green, A. (2025) <https://BioRender.com/spmuz42>

CDK4/6i are also in clinical trials for prostate cancer (Table 1), however these have not specifically assessed outcomes in the bone metastatic setting. Thus far, CDK4/6i have been well-tolerated when combined with other therapies, but clinical efficacy has not been strongly evidenced. The phase III CYCLONE 2 trial found no improvement in radiographic PFS by adding abemaciclib to abiraterone in castrate-resistance prostate cancer [123]. Similarly, a phase II trial found no radiographic PFS benefit over androgen deprivation therapy alone in Rb-positive metastatic hormone-sensitive prostate cancer [124]. Other combinations are in phase I/II investigation [125] (NCT02555189, NCT02905318), and given the promising efficacy in breast

cancer bone metastasis, it is of interest to determine whether CDK4/6i could be similarly effective in prostate cancer bone metastasis.

Selective Oestrogen Receptor Degraders

Oestrogen receptor (ER)-targeted therapies are crucial for treating ER-positive breast cancer and are used as long-term adjuvant therapies to prevent recurrence from dormant DTCs [126]. Selective ER degraders/downregulators (SERDs) have been developed to overcome endocrine resistance, particularly in *ESR1*-mutant breast cancers [113, 114], which results in the constitutive activation of ER and

reduced sensitivity to standard oestrogen therapies (ETs) [113, 127]. SERDs could prevent reactivation by overcoming endocrine resistance in dormant DTCs. Currently, fulvestrant is the only FDA approved SERD, used in ET-refractory advanced/metastatic breast cancer [128–130]. New orally bioavailable SERDs (Table 1) show promising efficacy and tolerability in early and advanced breast cancer [128]. Early data from the coopERA trial showed a reduction in Ki-67 from baseline to week 2 in early breast cancer [131], suggesting SERDs may reduce tumour proliferation. Ongoing phase III trials are evaluating their potential in ER+HER2- early breast cancer [132, 133].

5-azacytidine and ATRA

ATRA and 5-azacytidine has shown promise preclinically in dormant HNSCC and breast cancer [83, 84]. This motivated an ongoing clinical trial with 5-azacytidine and ATRA to induce dormancy and prevent relapse in biochemically recurrent prostate cancer patients. The combination appears safe and well tolerated, and a small subset of patients demonstrated clinical activity [134].

Direct Targeting of Dormant Cancer Cells

Therapies that directly kill dormant cells could ultimately be curative if every dormant cancer cell is targeted. Some agents that target dormancy biology have shown promising results preclinically and are now in trials assessing bone metastasis.

Hydroxychloroquine

Cancer cell dormancy is reliant on autophagy [92, 105–107], and the autophagy inhibitor hydroxychloroquine (HCQ) is in clinical trials to prevent recurrence in breast cancer specifically by targeting dormant DTCs (Table 1). HCQ is safe and tolerated with palbociclib in patients with metastatic breast cancer [135]. Ongoing PALAVY (HCQ or avelumab (PD-L1 inhibitor)±palbociclib, NCT04841148) and ABBY (abemaciclib±HCQ, NCT04523857) trials will determine efficacy in eliminating DTCs and prevention of disease recurrence. There are several prostate cancer trials [136–138] (NCT06408298), although these are not specifically assessing dormancy or bone metastasis.

PERK Inhibitors

Preclinical studies have demonstrated the efficacy of PERK inhibition in HER-2 breast cancer [101]. The PERK inhibitor HC-5404 showed safety, tolerability and promising

efficacy in a phase I trial in patients with advanced solid tumours [139]. However, further trials are needed to determine whether PERK inhibitors can effectively target dormant cells in bone.

Conclusions

Recent technological advances, particularly in single cell omics, have rapidly advanced the dormancy field, uncovering key traits, mechanisms and potential therapeutic targets. Perivascular MSCs (NG2+Nestin+) have emerged as pro-dormancy niche cells, yet the specific osteoblast-lineage subtypes and signalling pathways within the endosteal niche remain undefined, as does the likely complex role of immune cells. While dormancy-maintaining treatments are not curative, they can delay progression, and clinical trials are underway that exploit intrinsic vulnerabilities of dormant cells. To identify patients likely to benefit from dormancy therapies, efforts should focus on mapping conserved niche-cancer interactions across cancer types, and whether cellular heterogeneity enables persistence of resistant clones. With ongoing clinical trials, and new targets emerging from preclinical studies, the coming years are likely to reveal whether dormancy therapeutics can meaningfully benefit and extend the lives of patients with cancer in their bones.

Key References

- Zhang et al. (2021) *The bone microenvironment invigorates metastatic seeds for further dissemination*. Cell.

This paper used evolving barcodes to show that the bone microenvironment reprogrammes disseminated breast and prostate cancer cells making them more likely to further metastasise to bone and other organs.

- Nobre et al. (2021) *Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2*. Nature Cancer.

The paper identified that perivascular MSCs promote dormancy of disseminated breast cancer cells via TGF-β2 and BMP7. Disruption of this pro-dormancy niche led to a reduction in dormant cells.

- Vera-Ramirez et al. (2019) *Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence*. Nature Communications.

The authors identify dormant breast cancer cells are sensitive to autophagy inhibitor hydroxychloroquine. This study has led to ongoing clinical trials using hydroxychloroquine and CDK4/6i to prevent relapse in breast cancer, with promising early findings.

- Khoo et al. (2019) *A niche-dependent myeloid transcriptome signature defines dormant myeloma cells*. Blood.

This paper revealed the single-cell transcriptome of dormant vs. proliferating myeloma cells mimics that of different blood cells - monocytes and macrophages. The dormant phenotype is dependent on the microenvironment and dormancy could be disrupted with inhibitors of AXL.

- Liu et al., (2025) Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization. Cell Genomics.

While not focused on dormancy, this paper used single cell RNA sequencing of 42 patient samples to reveal three distinct types of immune enrichment ecosystems in bone metastasis, and that these were not determined by primary cancer site.

Author Contributions C.J.H, G.R.S, A.F. and A.C.G wrote the main manuscript text, G.R.S prepared figure 3, A.F. prepared figure 1 and A.C.G and C.J.H. prepared figure 2. All authors reviewed the manuscript.

Data Availability No datasets were generated or analysed during the current study.

Declarations

Competing Interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Townson JL, Chambers AF. Dormancy Solitary Metastatic Cells Cell Cycle. 2006;5(16):1744–50.
2. Risson E, et al. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2020;1(7):672–80.
3. Gimbrone MA, et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972;136(2):261–76.
4. Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20(7):398–411.
5. Weston WA, Barr AR. A cell cycle centric view of tumour dormancy. Br J Cancer. 2023;129(10):1535–45.
6. d'Adda di Fagagna. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7):512–22.
7. Kim JH, Brown SL, Gordon MN. Radiation-induced senescence: therapeutic opportunities. Radiat Oncol. 2023;18(1):10.
8. Takasugi M, et al. The role of cellular senescence and SASP in tumour microenvironment. FEBS J. 2023;290(5):1348–61.
9. Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer. 2016;16(6):373–86.
10. Lawson MA, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6:8983.
11. Budczies J, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015;6(1):570–83.
12. Morgan TM, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15(2):677–83.
13. Tjensvoll K, et al. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome. BMC Cancer. 2012;12:190.
14. Schindlbeck C, et al. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. J Cancer Res Clin Oncol. 2013;139(6):1055–62.
15. Hartkopf AD, et al. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis. Eur J Cancer. 2014;50(15):2550–9.
16. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91(1):80–5.
17. Pfizenmaier J, et al. Telomerase activity in disseminated prostate cancer cells. BJU Int. 2006;97(6):1309–13.
18. Weckermann D, et al. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol. 2001;166(2):699–703.
19. Green AC, et al. The characterization of distinct populations of murine skeletal cells that have different roles in B lymphopoiesis. Blood. 2021;138(4):304–17.
20. Wu Q, et al. Resilient anatomy and local plasticity of naive and stress haematopoiesis. Nature. 2024;627(8005):839–46.
21. Zhang W, et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell. 2021;184(9):2471–e248620.
22. Rosano D, et al. Long-term multimodal recording reveals epigenetic adaptation routes in dormant breast cancer cells. Cancer Discov. 2024;14(5):866–89.
23. Allocca G, et al. The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche *in vivo*. J Bone Oncol. 2019;17:100244.
24. Shiozawa Y, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121(4):1298–312.

25. Wang H, et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. *Cancer Cell*. 2015;27(2):193–210.
26. Hughes R, et al. Osteoblast-derived paracrine and juxtacrine signals protect disseminated breast cancer cells from stress. *Cancers (Basel)*. 2021;13(6):1366.
27. Nguyen NTK, et al. Acute myeloid leukemia stem cells remodel the bone marrow niche via TGF- β -activated Alcam(+) bone lining cells, creating a self-sustaining environment. *Leukemia*. 2025;39(7):1778–82.
28. Chen Z, et al. TRIM44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche via HIF-1 α stabilization. *Leukemia*. 2019;33(2):469–86.
29. Khoo WH, et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. *Blood*. 2019;134(1):30–43.
30. Ren D, et al. Wnt5a induces and maintains prostate cancer cells dormancy in bone. *J Exp Med*. 2018;216(2):428–49.
31. Nobre AR, et al. Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF- β 2. *Nat Cancer*. 2021;2(3):327–39.
32. Ghajar CM, et al. The perivascular niche regulates breast tumour dormancy. *Nat Cell Biol*. 2013;15(7):807–17.
33. Carlson P, et al. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. *Nat Cell Biol*. 2019;21(2):238–50.
34. Liu F, et al. Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization. *Cell Genom*. 2025. <https://doi.org/10.1016/j.xgen.2025.100888>
35. Jung Y, et al. Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. *Oncotarget*. 2016. <https://doi.org/10.18632/oncotarget.8365>
36. Kobayashi A, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. *J Exp Med*. 2011;208(13):2641–55.
37. Bragado P, et al. Tgf- β 2 dictates disseminated tumour cell fate in target organs through TGF- β -RIII and p38 α / β signalling. *Nat Cell Biol*. 2013;15(11):1351–61.
38. Johnson RW, et al. Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. *Nat Cell Biol*. 2016;18(10):1078–89.
39. Ren Q, et al. Gene expression predicts dormant metastatic breast cancer cell phenotype. *Breast Cancer Res*. 2022;24(1):10.
40. Yumoto K, et al. Axl is required for TGF- β 2-induced dormancy of prostate cancer cells in the bone marrow. *Sci Rep*. 2016;6:36520.
41. Axelrod HD, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. *Mol Cancer Res*. 2019;17(2):356–69.
42. Shiozawa Y, Pedersen EA, Taichman RS. GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. *Exp Hematol*. 2010;38(2):132–40.
43. Ottewill PD, et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. *Endocr Relat Cancer*. 2014;21(5):769–81.
44. Ottewill PD, et al. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. *Clin Cancer Res*. 2014;20(11):2922–32.
45. Ottewill PD, et al. OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. *Int J Cancer*. 2015;137(4):968–77.
46. Vidula N, et al. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant Zoledronic acid. *NPJ Breast Cancer*. 2021;7(1):113.
47. Tulotta C, et al. IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. *NPJ Breast Cancer*. 2021;7(1):95.
48. Holen I, et al. IL-1 drives breast cancer growth and bone metastasis in vivo. *Oncotarget*. 2016;7(46):75571–84.
49. Eyre R, et al. Microenvironmental IL1 β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signaling. *Nat Commun*. 2019;10(1):5016.
50. Zhou J, Ottewill PD. The role of IL-1B in breast cancer bone metastasis. *J Bone Oncol*. 2024;46:100608.
51. Wang H, et al. The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability. *Cancer Cell*. 2018;34(5):823–e8397.
52. Fairfield H, et al. Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype. *Cancer Res*. 2021;81(3):634–47.
53. Plakhova N, et al. Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma. *Leukemia*. 2025;39(6):1464–75.
54. Borges GA, et al. Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression. *Leukemia*. 2025;39(5):1206–17.
55. Marin I, et al. Cellular senescence is immunogenic and promotes antitumor immunity. *Cancer Discov*. 2023;13(2):410–31.
56. Wiecek AJ, et al. Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer. *Genome Biol*. 2023;24(1):128.
57. Nobre AR, et al. ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung. *Nat Cancer*. 2022;3(10):1165–80.
58. Barkan D, et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. *Cancer Res*. 2010;70(14):5706–16.
59. Barney LE, et al. Tumor cell-organized fibronectin maintenance of a dormant breast cancer population. *Sci Adv*. 2020;6(11):eaaz4157.
60. Di Martino JS, et al. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. *Nat Cancer*. 2022;3(1):90–107.
61. McCabe NP, et al. Prostate cancer specific integrin α v β 3 modulates bone metastatic growth and tissue remodeling. *Oncogene*. 2007;26(42):6238–43.
62. Spencer JA, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. *Nature*. 2014;508(7495):269–73.
63. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. *Cell Stem Cell*. 2010;7(2):150–61.
64. Kawano Y, et al. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells. *Int J Oncol*. 2013;43(6):1809–16.
65. Muz B, et al. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. *Blood Cancer J*. 2014;4(12):e262.
66. Fluegen G, et al. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. *Nat Cell Biol*. 2017;19(2):120–32.
67. Guilatco AJ, et al. Melphalan-induced multiple myeloma cells exhibit a senescent-like dormant phenotype. *Blood*. 2023;142(Supplement 1):6603–6603.
68. Schewe DM, Aguirre-Ghisso JA. Inhibition of eIF2 α dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. *Cancer Res*. 2009;69(4):1545–52.
69. Malumbres M. Cyclin-dependent kinases. *Genome Biol*. 2014;15(6):122.
70. Pardee AB. A restriction point for control of normal animal cell proliferation. *Proc Natl Acad Sci U S A*. 1974;71(4):1286–90.

71. Pennycook BR, Barr AR. Restriction point regulation at the crossroads between quiescence and cell proliferation. *FEBS Lett*. 2020. <https://doi.org/10.1002/1873-3468.13867>
72. Kwon JS, et al. Controlling depth of cellular quiescence by an Rb-E2F network switch. *Cell Rep*. 2017;20(13):3223–35.
73. Endo H, et al. Dormancy of cancer cells with suppression of AKT activity contributes to survival in chronic hypoxia. *PLoS ONE*. 2014;9(6):e98858.
74. Pernas S, et al. CDK4/6 inhibition in breast cancer: current practice and future directions. *Ther Adv Med Oncol*. 2018;10:1758835918786451.
75. Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. *Gut*. 2017;66(7):1286–96.
76. Sosa MS, et al. ERK1/2 and p38 α / β signaling in tumor cell quiescence: opportunities to control dormant residual disease. *Clin Cancer Res*. 2011;17(18):5850–7.
77. Rehman SK, et al. Colorectal cancer cells enter a Diapause-like DTP state to survive chemotherapy. *Cell*. 2021;184(1):226–e24221.
78. Moore LD, Le T, Fan G. DNA methylation its basic function. *Neuropsychopharmacol*. 2013;38(1):23–38.
79. Clements ME, et al. Hdac inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer. *Oncogene*. 2021;40(34):5314–26.
80. Edwards CM, et al. HDAC inhibitors stimulate LIFR when it is repressed by hypoxia or PTHrP in breast cancer. *J Bone Oncol*. 2021;31:100407.
81. Owen KL, et al. Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. *EMBO Rep*. 2020;21(6):e50162.
82. Gao H, et al. Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. *Proc Natl Acad Sci U S A*. 2014;111(46):16532–7.
83. Singh DK, et al. 5-azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF- β -SMAD4 signaling. *Cell Rep*. 2023;42(6):112560.
84. Sosa MS, et al. NR2F1 controls tumour cell dormancy via SOX9- and RAR β -driven quiescence programmes. *Nat Commun*. 2015;6(1):6170.
85. Khalil BD, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. *J Exp Med*. 2021. <https://doi.org/10.1084/jem.20210836>
86. Almog N, et al. Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. *PLoS ONE*. 2012;7(8):e44001.
87. Tiram G, et al. Identification of dormancy-associated MicroRNAs for the design of Osteosarcoma-targeted dendritic polyglycerol nanopolyplexes. *ACS Nano*. 2016;10(2):2028–45.
88. Ghiso JAA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. *J Cell Biol*. 1999;147(1):89–104.
89. Aguirre-Ghiso JA, et al. Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy *in vivo*. *Mol Biol Cell*. 2001;12(4):863–79.
90. El Touny LH, et al. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. *J Clin Invest*. 2014;124(1):156–68.
91. Aguirre Ghiso JA. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells *in vivo*. *Oncogene*. 2002;21(16):2513–24.
92. Vera-Ramirez L, et al. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. *Nat Commun*. 2018;9(1):1944.
93. Lu Z, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. *J Clin Invest*. 2008;118(12):3917–29.
94. Ranganathan AC, et al. Functional coupling of p38-induced up-regulation of bip and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. *Cancer Res*. 2006;66(3):1702–11.
95. Ranganathan AC, et al. Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival. *Cancer Res*. 2008;68(9):3260–8.
96. Lebeau J, et al. The PERK arm of the unfolded protein response regulates mitochondrial morphology during acute endoplasmic reticulum stress. *Cell Rep*. 2018;22(11):2827–36.
97. Avivar-Valderas A, et al. PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment. *Mol Cell Biol*. 2011;31(17):3616–29.
98. Pranzini E, Raugei G, Taddei ML. Metabolic features tumor dormancy: possible therapeutic strategies. *Cancers (Basel)*. 2022;14(3), 547. <https://doi.org/10.3390/cancers14030547>
99. Butturini E, et al. Tumor dormancy and interplay with hypoxic tumor microenvironment. *Int J Mol Sci*. 2019;20(17):4305.
100. Bobrovnikova-Marjon E, et al. PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. *Oncogene*. 2010;29(27):3881–95.
101. Calvo V, et al. A PERK-specific inhibitor blocks metastatic progression by limiting integrated stress response-dependent survival of quiescent cancer cells. *Clin Cancer Res*. 2023;29(24):5155–72.
102. Rasche L, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. *Nat Commun*. 2022;13(1):4517.
103. Landau HJ, et al. Accelerated single cell seeding in relapsed multiple myeloma. *Nat Commun*. 2020;11(1):3617.
104. Rustad EH, et al. Timing the initiation of multiple myeloma. *Nat Commun*. 2020;11(1):1917.
105. Sosa MS, et al. Regulation of tumor cell dormancy by tissue microenvironments and autophagy. *Adv Exp Med Biol*. 2013;734:73–89.
106. Bildik G, et al. DIRAS3: an imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy, and tumor dormancy. *Mol Cancer Ther*. 2022;21(1):25–37.
107. Vijayaraghavan S, et al. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic Cyclin E negative cancers. *Nat Commun*. 2017;8:15916.
108. National Institute for Health and Care Excellence. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. 2022 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/ta836/resources/palbociclib-with-fulvestrant-for-treating-hormone-receptorpositive-her2negative-advanced-breast-cancer-after-endocrine-therapy-pdf-82613434646725>
109. National Institute for Health and Care Excellence. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. 2017 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/ta495/resources/palbociclib-with-an-aromatase-inhibitor-for-previously-untreated-hormone-receptorpositive-her2negative-locally-advanced-or-metastatic-breast-cancer-pdf-82605088634821>
110. National Institute for Health and Care Excellence. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. 2017 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/ta496/resources/ribociclib-with-an-aromatase-inhibitor-for-previously-untreated-hormone-receptorpositive-her2negative-locally-advanced-or-metastatic-breast-cancer-pdf-82605090314437>

111. National Institute for Health and Care Excellence. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. 2021 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/ta687/resources/ribociclib-with-fulvestrant-for-treating-hormone-receptorpositive-her2negative-advanced-breast-cancer-after-endocrine-therapy-pdf-82609385092549>
112. National Institute for Health and Care Excellence. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. 2021 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/ta725/resources/abemaciclib-with-fulvestrant-for-treating-hormone-receptorpositive-her2negative-advanced-breast-cancer-after-endocrine-therapy-pdf-82611195718597>
113. Fanucci K, Mayer EL. The state of the science of oral selective oestrogen receptor degraders. *Lancet Oncol*. 2024;25(11):1388–9.
114. Grinshpun A, et al. Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. *NPJ Breast Cancer*. 2024;10(1):42.
115. National Institute for Health and Care Excellence. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]. 2025 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11090>
116. Finn RS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med*. 2016;375(20):1925–36.
117. Rugo HS, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. *Breast Cancer Res Treat*. 2019;174(3):719–29.
118. Johnston SRD, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2023;24(1):77–90.
119. Hortobagyi GN, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. *Ann Oncol*. 2025;36(2):149–57.
120. Gnant M, et al. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). *J Clin Oncol*. 2022;40(3):282–93.
121. Loibl S, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial. *J Clin Oncol*. 2021;39(14):1518–30.
122. National Institute for Health and Care Excellence. Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. 2022 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/ta810/resources/abemaciclib-with-endocrine-therapy-for-adjuvant-treatment-of-hormone-receptorpositive-her2negative-nodepositive-early-breast-cancer-at-high-risk-of-recurrence-pdf-82613303636677>
123. Smith MR, et al. Cyclone 2: a phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer. *J Clin Oncol*. 2024;42(16suppl):5001–5001.
124. Palmboos PL, et al. A randomized phase II study of androgen deprivation therapy with or without Palbociclib in RB-positive metastatic hormone-sensitive prostate cancer. *Clin Cancer Res*. 2021;27(11):3017–27.
125. de Kouchkovsky I, et al. A phase Ib/II study of the CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer. *Clin Cancer Res*. 2022;28(8):1531–9.
126. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. 2018 2025 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#endocrine-therapy-for-hormone-receptor-positive-breast-cancer>
127. Jeselsohn R, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. *Nat Rev Clin Oncol*. 2015;12(10):573–83.
128. Cescon DW, et al. Therapeutic targeting of minimal residual disease to prevent late recurrence in Hormone-Receptor positive breast cancer: challenges and new approaches. *Front Oncol*. 2021;11:667397.
129. National Institute for Health and Care Excellence. Fulvestrant for untreated locally advanced or metastatic oestrogenreceptor positive breast cancer. 2018 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/ta503/resources/fulvestrant-for-untreated-locally-advanced-or-metastatic-oestrogenreceptor-positive-breast-cancer-pdf-82606717862341>
130. National Institute for Health and Care Excellence. Fulvestrant for the treatment of locally advanced or metastatic breast cancer. 2011 [cited 2025 July 16th]; Available from: <https://www.nice.org.uk/guidance/ta239/resources/fulvestrant-for-the-treatment-of-locally-advanced-or-metastatic-breast-cancer-pdf-82600378991557>
131. Fasching PA, et al. Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2–eBC): final analysis of the randomized, open-label, international phase 2 CoopERA BC study. *J Clin Oncol*. 2022;40(16suppl):589–589.
132. Geyer C, et al. LidERA breast cancer (BC): phase III adjuvant study of Giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with Estrogen receptor-positive, HER2-negative early BC (ER+, HER2–eBC). *J Clin Oncol*. 2023;41(16suppl):TPS616–616.
133. Jhaveri K, et al. Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET. *Cancer Res*. 2023;83(5Supplement):pOT1-01.
134. Patel VG, et al. Abstract CT223: dormancy reprogramming therapy of 5-azacitidine (AZA) and all-trans retinoic acid (ATRA) in biochemically recurrent prostate cancer. *Cancer Res*. 2024;84(7Supplement):CT223–223.
135. Raghavendra AS, et al. Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2–breast cancer. *NPJ Breast Cancer*. 2025;11(1):7.
136. George MA, et al. Autophagic cell death with hydroxychloroquine in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. *J Clin Oncol*. 2017;35(6suppl):102–102.
137. Burikhanov R, et al. Chloroquine-inducible par-4 secretion is essential for tumor cell apoptosis and inhibition of metastasis. *Cell Rep*. 2017;18(2):508–19.
138. Kim JK, et al. Hydroxychloroquine effects on tumor suppressor PAR-4 levels in patients with oligometastatic prostate cancer: results from a phase-2 trial. *J Clin Oncol*. 2025;43(5suppl):233–233.
139. Dudek AZ, et al. A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors. *J Clin Oncol*. 2024;42(16suppl):e15118–15118.
140. Johnston SRD, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). *J Clin Oncol*. 2020;38(34):3987–98.

141. Bidard FC, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. *J Clin Oncol.* 2022;40(28):3246–56.
142. Martín M, et al. Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study. *J Clin Oncol.* 2024;42(18):2149–60.
143. DeMichele A, et al. 244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (CLEVER). *Ann Oncol.* 2023;34:S281.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.